Study Shows AstraZeneca's Antibody Pill Over 80% Effective

Click the image below to enlarge the infographic.
  • AstraZeneca's antibody pill has been shown to be found to be highly effective at preventing COVID-19, particularly in people who may not respond well to vaccines
  • The data revealed that patients given a single injection of the antibody treatment, known as AZD7442, were 83 percent less likely to develop symptomatic COVID-19 than poeple who received a placebo
  • An early anaysis conducted three months after the treatment was administered found that the drug lowered the risk of severe disease by 77 percent.
  • Six months on from the treatment being administered, no severe COVID-19 cases or deaths were recorded among those that received the antibody cocktail. Among those that received the placebo, five participants contracted severe COVID-19 and two died from the infection within six months of the trial
  • More than 75 percent of people enrolled in the trial had underlying medical conditions that put them at high risk of severe COVID-19, including conditions that compromised their immune system, potentially reducing their reponse to vaccination